Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Buckmelter
Alexander J. Buckmelter, Boulder, CO US
| Patent application number | Description | Published |
|---|---|---|
| 20110110889 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 05-12-2011 |
Alexandre Buckmelter, Superior, CO US
| Patent application number | Description | Published |
|---|---|---|
| 20090048279 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS - This invention provides quinazoline analogs of Formula I: | 02-19-2009 |
| 20090270621 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS - This invention concerns quinazoline analogs of Formula I: | 10-29-2009 |
Alexandre J. Buckmelter, Boulder, CO US
| Patent application number | Description | Published |
|---|---|---|
| 20110092479 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 04-21-2011 |
Alexandre J. Buckmelter, Superior, CO US
| Patent application number | Description | Published |
|---|---|---|
| 20090060968 | INHIBITORS OF PHOSPHATASES - The present invention relates to compounds that inhibit phosphatases, compositions thereof, and methods of using those compounds and compositions for treating diseases. | 03-05-2009 |
| 20100063066 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 03-11-2010 |